Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 21, 2016

Study Completion Date

December 21, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Panobinostat

Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.

DRUG

Lenalidomide

Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.

DRUG

Dexamethasone

Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Ajai Chari

OTHER